Table 2

Recommendation for Chelation Therapy

2012 Recommendation2014 Focused Update RecommendationComment
Class III: No Benefit
  • 1. Chelation therapy is not recommended with the intent of improving symptoms or reducing cardiovascular risk in patients with SIHD (38–41). (Level of Evidence: C)

Class IIb
  • 1. The usefulness of chelation therapy is uncertain for reducing cardiovascular events in patients with SIHD (38–42). (Level of Evidence: B)

Modified recommendation (changed Class of Recommendation from III: No Benefit to IIb and Level of Evidence from C to B).

SIHD indicates stable ischemic heart disease.